azacitidine has been researched along with Blast Crisis in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (21.88) | 18.2507 |
| 2000's | 3 (9.38) | 29.6817 |
| 2010's | 18 (56.25) | 24.3611 |
| 2020's | 4 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Y; Huang, P; Li, J; Liu, C; Liu, H; Liu, Q; Wang, Y; Wu, L; Yang, Z; Zheng, Y | 1 |
| Bobin, A; Cayssials E, E; Chomel, JC; Desmier, D; Gallego-Hernanz, P; Gardeney, H; Maillard, N; Moya, N; Systchenko, T; Torregrosa, J; Vonfeld, M | 1 |
| Garcia-Horton, A; Gupta, V; Maze, D; McNamara, CJ; Murphy, T; Sibai, H | 1 |
| Al-Kali, A; Alkhateeb, H; Begna, KH; Elliott, MA; Foran, JM; Gangat, N; Guglielmelli, P; Hanson, CA; Litzow, MR; Mannelli, F; Palmer, JM; Pardanani, A; Patnaik, MM; Szuber, N; Tefferi, A; Vannucchi, AM | 1 |
| Comerford, CM; Langabeer, SE; Murphy, PT; Quinn, J | 1 |
| Bertsch, HP; Claßen, A; Kitz, J; Lippert, U; Overbeck, T; Perske, C; Schön, MP | 1 |
| Füreder, W; Gleixner, K; Grünberger, B; Hoermann, G; Kornauth, C; Schwarzinger, I; Sperr, WR; Thalhammer, R; Valent, P | 1 |
| Berthou, C; Boyer-Perrard, F; Chauveau, A; Couturier, MA; Dagorne, A; Douet-Guilbert, N; Guillerm, G; Houot, R; Hunault, M; Ianotto, JC; Le Calloch, R; Lippert, É; Luycx, O; Malou, M; Mollard, LM; Quintin-Roué, I; Thepot, S; Ugo, V | 1 |
| Anaclerico, B; Andriani, A; Aroldi, A; Breccia, M; Carmosino, I; Centra, A; Di Veroli, A; Elli, E; Fianchi, L; Foà, R; Latagliata, R; Martini, V; Montanaro, G; Montanaro, M; Niscola, P; Trapè, G; Villivà, N; Voso, MT | 1 |
| Auger, N; Bennaceur-Griscelli, A; Bourhis, JH; Castaigne, S; de Botton, S; Ghez, D; Ianotto, JC; Micol, JB; Pasquier, F; Rigaudeau, S; Rousselot, P; Saada, V; Spentchian, M; Terré, C | 1 |
| Galli, S; Harrison, CN; Keohane, C; McLornan, DP; Mwirigi, A; Radia, DH; Raj, K | 1 |
| Adès, L; Berthon, C; Bouscary, D; Caillot, D; Cluzeau, T; Dartigeas, C; Delaunay, J; Devidas, A; Dombret, H; Fenaux, P; Gardin, C; Guièze, R; Ifrah, N; Itzykson, R; Marolleau, JP; Plantier, I; Prébet, T; Recher, C; Stamatoullas, A; Taksin, AL; Thépot, S; Turlure, P; Vey, N | 1 |
| Al-Ali, HK; Beach, CL; Bernal del Castillo, T; Butrym, A; Candoni, A; Cavenagh, J; Döhner, H; Dombret, H; Falantes, J; Jang, JH; Kumar, R; Lucy, LM; Martinelli, G; McIntyre, H; Minden, MD; Noppeney, R; Récher, C; Sandhu, I; Schuh, AC; Selleslag, D; Seymour, JF; Songer, S; Stone, RM; Wierzbowska, A | 1 |
| Alimena, G; Andriani, A; Andrizzi, C; Ciccone, F; De Gregoris, C; Di Veroli, A; Latagliata, R; Maurillo, L; Montanaro, M; Villivà, N; Voso, MT | 1 |
| Berthon, C; Delaunay, J; Dreyfus, F; Esterni, B; Fenaux, P; Itzykson, R; Kulasekararaj, A; Micol, JB; Mufti, G; Prebet, T; Recher, C; Roux, C; Sebert, M; Thepot, S; Vey, N; Wanquet, A | 1 |
| Badar, T; Borthakur, G; Cortes, JE; Daver, N; Jabbour, E; Kantarjian, HM; Newberry, KJ; Pemmaraju, N; Pierce, SR; Ravandi, F; Verstovsek, S | 1 |
| Huls, G | 1 |
| Aul, C; Baron, F; Becker, H; de Witte, T; Fiaccadori, V; Ganser, A; Germing, U; Giagounidis, A; Hagemeijer, A; Labar, B; Lübbert, M; Muus, P; Pflüger, KH; Platzbecker, U; Rüter, BH; Salih, HR; Schaefer, HE; Selleslag, D; Suciu, S; Wijermans, PW | 1 |
| Aoyama, K; Choi, K; Hasegawa, N; Iseki, T; Isshiki, Y; Iwama, A; Kawajiri-Manako, C; Koide, S; Mimura, N; Muto, T; Nagao, Y; Nakaseko, C; Ohwada, C; Sakai, S; Sakaida, E; Shimizu, R; Starczynowski, DT; Takeda, Y; Takeuchi, M; Togasaki, E; Tsukamoto, S; Yokote, K | 1 |
| Backstrom, J; Beach, CL; Dombret, H; Fenaux, P; Gattermann, N; Germing, U; Gore, S; Hellström-Lindberg, E; List, AF; McKenzie, D; Mufti, GJ; Santini, V; Sanz, G; Seymour, JF; Silverman, LR; Zimmerman, L | 1 |
| Leary, C; Lowery-Nordberg, M; Stephens, J; Turturro, F; Veillon, D | 1 |
| Bhatla, T; Brown, P; Burke, MJ; Carroll, WL; Morrison, DJ; Raetz, EA; Wang, J | 1 |
| Andreeff, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Issa, JP; Kantarjian, HM; Keating, M; O'Brien, S; Rios, MB; Shan, J; Talpaz, M | 1 |
| Chang, JG; Chen, YH; Hsiao, HH; Lin, HY; Lin, PM; Lin, SF; Liu, TC; Liu, YC; Tang, KP; Yang, MY | 1 |
| Cortes, J; Garcia-Manero, G; Gharibyan, V; Issa, JP; Jones, D; Kantarjian, HM; Morris, GM; O'brien, S; Oki, Y; Verstovsek, S | 1 |
| Bennett, J; Browman, G; Bryant, J; Goldberg, J; Grunwald, H; Gryn, J; Larson, R; Preisler, H; Raza, A; Vogler, R | 1 |
| Catapano, CV; Colombo, T; Conter, V; Damia, G; Gervasoni, M; Giudici, G; Limonta, M; Liso, V; Masera, G; Specchia, G | 1 |
| Beran, M; de Vos, D; Estey, E; Giralt, S; Kantarjian, HM; Keating, M; Kornblau, S; O'Brien, SM; Rios, MB; Talpaz, M | 1 |
| Estey, E; Kantarjian, HM; Keating, MJ; O'Brien, S; Plunkett, W; Rios, MB; Sorenson, M; Wilhelm, M | 1 |
| Beran, M; Cortes, J; Giles, FJ; Kantarjian, HM; Keating, MJ; Koller, CA; O'Brien, S; Rios, MB; Sacchi, S; Talpaz, M | 1 |
| Arlin, Z; Bennett, JM; Dutcher, JP; Eudey, L; Kellermeyer, R; O'Connell, M; Oken, M; Paietta, E; Rowe, J; Wiernik, PH | 1 |
| McCulloch, EA; Yang, GS | 1 |
10 trial(s) available for azacitidine and Blast Crisis
| Article | Year |
|---|---|
Azacitidine for the treatment of relapsed and refractory AML in older patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Risk Factors; Survival Rate | 2015 |
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Female; Follow-Up Studies; Humans; International Agencies; Leukemia, Myeloid, Acute; Male; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate | 2015 |
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS St
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Decitabine; Disease-Free Survival; Female; Humans; Male; Middle Aged; Survival Rate | 2015 |
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Bone Marrow Cells; Female; Follow-Up Studies; Humans; International Agencies; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2010 |
Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Cell Line, Tumor; Child; Child, Preschool; Cohort Studies; Decitabine; DNA Methylation; Female; Gene Expression Regulation, Leukemic; Gene Silencing; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, B-Cell; Male; Vorinostat | 2012 |
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Blast Crisis; Decitabine; DNA Methylation; Female; Genes, abl; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Survival Analysis; Treatment Outcome | 2007 |
Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study.
Topics: Adult; Azacitidine; Biopsy; Blast Crisis; Bone Marrow; Cell Cycle; DNA, Neoplasm; Female; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Outcome Assessment, Health Care; Recurrence | 1993 |
Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Decitabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged | 1997 |
Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blast Crisis; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Salvage Therapy; Treatment Outcome | 1999 |
Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Drug Evaluation; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Mitoxantrone; Remission Induction | 1992 |
22 other study(ies) available for azacitidine and Blast Crisis
| Article | Year |
|---|---|
Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for de novo lymphoid blast phase-chronic myeloid leukemia.
Topics: Azacitidine; Blast Crisis; Bridged Bicyclo Compounds, Heterocyclic; Fusion Proteins, bcr-abl; Humans; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
Topics: Aged; Aged, 80 and over; Azacitidine; Blast Crisis; Humans; Myeloproliferative Disorders; Quality of Life; Treatment Outcome | 2023 |
Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series.
Topics: Azacitidine; Blast Crisis; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myelomonocytic, Chronic; Sulfonamides | 2021 |
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; Female; Humans; Male; Middle Aged; Myeloproliferative Disorders; Retrospective Studies; Sulfonamides; Survival Analysis; Treatment Outcome | 2021 |
Molecular profiling and targeted inhibitor therapy in atypical chronic myeloid leukaemia in blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; DNA Mutational Analysis; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Leukemia cutis in a patient with chronic myelomonocytic leukemia.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Diagnosis, Differential; Humans; Leukemia, Myelomonocytic, Chronic; Leukemic Infiltration; Male; Skin | 2018 |
Major response of PNH to an AML chemotherapy protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Cytarabine; Daunorubicin; Hemoglobinuria, Paroxysmal; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 2018 |
Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Cross-Sectional Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Palliative Care; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome | 2018 |
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Melphalan; Middle Aged; Mutation; Myeloproliferative Disorders; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Remission Induction; Retrospective Studies; Thrombocythemia, Essential; Treatment Outcome | 2019 |
Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Female; Hematologic Neoplasms; Humans; Male; Myeloproliferative Disorders; Nitriles; Pyrazoles; Pyrimidines | 2014 |
Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Disease Progression; Female; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome | 2015 |
Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Chromosome Aberrations; Chromosomes, Human, Pair 3; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate | 2015 |
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Decitabine; Female; Humans; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Primary Myelofibrosis; Prospective Studies; Remission Induction; Survival Analysis; Treatment Outcome | 2015 |
Azacitidine in AML: a treatment option?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Female; Humans; Leukemia, Myeloid, Acute; Male | 2015 |
Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Case-Control Studies; Cells, Cultured; CpG Islands; Decitabine; DNA Methylation; DNA-Binding Proteins; Exons; Female; Gene Expression Regulation, Leukemic; Gene Silencing; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Receptors, Steroid; Receptors, Thyroid Hormone | 2016 |
Caution using hypomethylating agents in myelodysplasia or myeloid leukemia with complex cytogenetics.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Chromosome Deletion; Female; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes | 2010 |
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Decitabine; DNA Modification Methylases; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged | 2003 |
Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3.
Topics: Adult; ARNTL Transcription Factors; Azacitidine; Basic Helix-Loop-Helix Transcription Factors; Blast Crisis; Cell Cycle Proteins; Circadian Rhythm; CLOCK Proteins; Cryptochromes; DNA Methylation; Down-Regulation; Flavoproteins; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nuclear Proteins; Period Circadian Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Trans-Activators; Transcription Factors | 2006 |
Cytotoxic activity and mechanism of action of 5-Aza-2'-deoxycytidine in human CML cells.
Topics: Antineoplastic Agents; Azacitidine; Blast Crisis; Cytarabine; Decitabine; DNA, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Time Factors; Tumor Cells, Cultured | 1993 |
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Decitabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Remission Induction; Salvage Therapy; Survival Analysis | 1999 |
A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia.
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Blast Crisis; Cell Survival; Cytarabine; Humans; Leukemia, Myeloid; Tumor Cells, Cultured | 1992 |